Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (Weighted Average) (2016 - 2025)

Northwest Biotherapeutics' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $92.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $92.9 million for Q4 2025, down 92.52% from a year ago — trailing twelve months through Dec 2025 was $92.9 million (down 92.52% YoY), and the annual figure for FY2025 was $92.9 million, down 92.52%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $92.9 million at Northwest Biotherapeutics, roughly flat from $92.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.2 billion in Q4 2024 to a low of $140243.0 in Q1 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $1.1 million (2023), against an average of $96.5 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 74513.61% in 2023, then tumbled 92.52% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $873517.0 in 2021, then crashed by 83.85% to $141048.0 in 2022, then skyrocketed by 74513.61% to $105.2 million in 2023, then surged by 1080.37% to $1.2 billion in 2024, then tumbled by 92.52% to $92.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $92.9 million, $92.9 million, and $92.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.